Literature DB >> 23379727

Preparation and technical considerations for percutaneous cannulation for veno-arterial extracorporeal membrane oxygenation.

Kathleen M Lamb1, Hitoshi Hirose, Nicholas C Cavarocchi.   

Abstract

BACKGROUND: The most frequent limb complications from peripheral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) are limb ischemia and localized bleeding. To minimize these risks, perfusion of the distal limb with peripheral percutaneous cannulation was done. TECHNIQUE: Percutaneous cannulation with a distal perfusion port was performed in all patients. During the VA-ECMO, distal limb perfusion was monitored using near-infrared spectroscopy to assess tissue oxygenation. At the decannulation, patch angioplasty was performed to prevent the development of narrowing of the artery at the cannulation site.
CONCLUSIONS: Using our standard technique, we have not experienced any limb loss related to ischemia or bleeding.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23379727     DOI: 10.1111/jocs.12058

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  14 in total

Review 1.  Veno-arterial extracorporeal membrane oxygenation: an overview of different cannulation techniques.

Authors:  Carlo Banfi; Matteo Pozzi; Marie-Eve Brunner; Fabio Rigamonti; Nicolas Murith; Damiano Mugnai; Jean-Francois Obadia; Karim Bendjelid; Raphaël Giraud
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 2.  Management of vascular complications of extra-corporeal membrane oxygenation.

Authors:  Anil K Pillai; Zagum Bhatti; Andrew J Bosserman; Manoj C Mathew; Kaza Vaidehi; Sanjeeva P Kalva
Journal:  Cardiovasc Diagn Ther       Date:  2018-06

Review 3.  Femoro-jugular cannulation in veno-venous extracorporeal membrane oxygenation PRO/CON.

Authors:  Martina Crivellari; Federico Pappalardo
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  [Acute respiratory distress syndrome and septic cardiomyopathy : successful application of veno-venoarterial extracorporeal membrane oxygenation].

Authors:  J Küstermann; A Gehrmann; M Kredel; T Wurmb; N Roewer; R M Muellenbach
Journal:  Anaesthesist       Date:  2013-08-07       Impact factor: 1.041

5.  Comparing Percutaneous to Open Access for Extracorporeal Membrane Oxygenation in Pediatric Respiratory Failure.

Authors:  Sarah B Cairo; Mary Arbuthnot; Laura Boomer; Michael W Dingeldein; Alexander Feliz; Samir Gadepalli; Christopher R Newton; Pramod Puligandla; Robert Ricca; Peter Rycus; Adam M Vogel; Guan Yu; Ziqiang Chen; David H Rothstein
Journal:  Pediatr Crit Care Med       Date:  2018-10       Impact factor: 3.624

Review 6.  [Veno-arterial extracorporeal membrane oxygenation. Indications, limitations and practical implementation].

Authors:  D Lunz; A Philipp; M Dolch; F Born; Y A Zausig
Journal:  Anaesthesist       Date:  2014-09       Impact factor: 1.041

7.  Extracorporeal membrane oxygenation in the acute treatment of cardiovascular collapse immediately post-partum.

Authors:  W Robert Leeper; Matthew Valdis; Robert Arntfield; L Ray Guo
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-08-13

8.  Unprotected left main percutaneous coronary intervention in acute coronary syndromes with extracorporeal life support backup.

Authors:  Dawid L Staudacher; Oliver Langner; Paul Biever; Christoph Benk; Manfred Zehender; Christoph Bode; Tobias Wengenmayer
Journal:  Scientifica (Cairo)       Date:  2015-02-25

Review 9.  Overview of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiogenic Shock.

Authors:  Adamantios Tsangaris; Tamas Alexy; Rajat Kalra; Marinos Kosmopoulos; Andrea Elliott; Jason A Bartos; Demetris Yannopoulos
Journal:  Front Cardiovasc Med       Date:  2021-07-07

10.  Prime time for veno-arterial extracorporeal membrane oxygenation in 24-7 interventional cardiology center?

Authors:  Marko Noc
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-01-12       Impact factor: 1.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.